glp-1 options for type 2 diabetes and obesity 2025 Agonists In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Dual and Triple Gut Peptide

Am J Chin Med

Strong response suggests maintaining current dosing

We defined psychiatric comorbidity as having alcohol and substance abuse (ICD-10: F10-F19), schizophrenia (ICD-10: F20-F29), bipolar disorders (ICD-10: F30-F31), major depression (ICD-10: F32-F33), eating disorders (ICD-10: F50), personality disorders (ICD-10: F60-F62) and psychotropics within 10 years prior to index date ( See Supplementary Table 1)

Methods Using nationwide data from the Research Data Centre of the Federal Statistical Office of Germany, a random 10% sample of all adult inpatients in 2022 was analyzed

Biopharma companies with GLP-1 (glucagon-like peptide-1) analogs, which have become a new trend in the obesity treatment market long dominated by appetite suppressants and fat-absorbance inhibitors, are upgrading their treatments